Completed PHASE3 INTERVENTIONAL 2-arm NCT01641510

PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants (PRAISE-GENE)

Phase 3 Study Comparing the Efficacy and Safety of Prasugrel and Clopidogrel in Acute Coronary Syndrome Patients With CYP2C19 Polymorphism Who Undergo Percutaneous Coronary Intervention.

Sponsor: Dong-A University

Conditions Acute Coronary Syndromes

Interventions Clopidogrel Prasugrel

Updated 8 times since 2017 Last updated: Feb 8, 2019 Started: Oct 31, 2013 Primary completion: Oct 31, 2018 Completion: Feb 28, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Acute Coronary Syndromes and is currently completed. Dong-A University leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Mar 2019 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed

▶ Show 3 earlier versions

Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE3
Sep 2017 — Jun 2018 [monthly]

Recruiting PHASE3
Jan 2017 — Sep 2017 [monthly]

Recruiting PHASE3

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dong-A University

Data source: Dong-A University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Busan, South Korea